연구성과로 돌아가기
2023 연구성과별 연구자 정보 (1808 / 2675)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| PHASE 1b/2a STUDY OF HETEROLOGOUS ChAdOx1-HBV/MVA-HBV THERAPEUTIC VACCINATION (VTP-300) COMBINED WITH LOW-DOSE NIVOLUMAB (LDN) IN VIRALLY-SUPPRESSED PATIENTS WITH CHB ON NUCLEOS(T)IDE ANALOGUES | Chen, Chi-Yi | Chen, CY | 9 | Chia Yi Christian Hosp, Chiayi, Taiwan | ||||||
| PHASE 1b/2a STUDY OF HETEROLOGOUS ChAdOx1-HBV/MVA-HBV THERAPEUTIC VACCINATION (VTP-300) COMBINED WITH LOW-DOSE NIVOLUMAB (LDN) IN VIRALLY-SUPPRESSED PATIENTS WITH CHB ON NUCLEOS(T)IDE ANALOGUES | Chuang, Wan-Long | Chuang, WL | 10 | Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hepatobiliary Sect, Dept Internal Med, Kaohsiung, Taiwan | C-9536-2009 | Chuang, Wan-Long | ||||
| PHASE 1b/2a STUDY OF HETEROLOGOUS ChAdOx1-HBV/MVA-HBV THERAPEUTIC VACCINATION (VTP-300) COMBINED WITH LOW-DOSE NIVOLUMAB (LDN) IN VIRALLY-SUPPRESSED PATIENTS WITH CHB ON NUCLEOS(T)IDE ANALOGUES | Lo, Gin-Ho | Lo, GH | 11 | E Da Hosp, Kaohsiung, Taiwan | ||||||
| PHASE 1b/2a STUDY OF HETEROLOGOUS ChAdOx1-HBV/MVA-HBV THERAPEUTIC VACCINATION (VTP-300) COMBINED WITH LOW-DOSE NIVOLUMAB (LDN) IN VIRALLY-SUPPRESSED PATIENTS WITH CHB ON NUCLEOS(T)IDE ANALOGUES | Tak, Won Young | Tak, WY | 12 | Kyungpook Natl Univ, Sch Med, Daegu, South Korea | ||||||
| PHASE 1b/2a STUDY OF HETEROLOGOUS ChAdOx1-HBV/MVA-HBV THERAPEUTIC VACCINATION (VTP-300) COMBINED WITH LOW-DOSE NIVOLUMAB (LDN) IN VIRALLY-SUPPRESSED PATIENTS WITH CHB ON NUCLEOS(T)IDE ANALOGUES | Tseng, Kuo-Chih | Tseng, KC | 13 | Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Chiayi, Taiwan | ||||||
| PHASE 1b/2a STUDY OF HETEROLOGOUS ChAdOx1-HBV/MVA-HBV THERAPEUTIC VACCINATION (VTP-300) COMBINED WITH LOW-DOSE NIVOLUMAB (LDN) IN VIRALLY-SUPPRESSED PATIENTS WITH CHB ON NUCLEOS(T)IDE ANALOGUES | Tseng, Kuo-Chih | Tseng, KC | 13 | Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Internal Med, Chiayi, Taiwan | ||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Lee, Jeeyun | Lee, J | 1 | I-7171-2015 | Lee, Jeeyun | |||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Shergill, Ardaman | Shergill, A | 2 | |||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Park, Haeseong | Park, H | 3 | AAL-7982-2021 | Park, Haeseong | |||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Lee, Keun-Wook | Lee, KW | 4 | |||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Arkenau, Hendrik-Tobias | Arkenau, HT | 5 | |||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Kang, Yoon-Koo | Kang, YK | 6 | ABL-4264-2022 | Kang, Yoon-Koo | |||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Olowokure, Olugbenga Olanrele | Olowokure, OO | 7 | |||||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Kim, Jong Gwang | Kim, JG | 8 | JXL-8219-2024 | Kim, Sung-Bae | |||||
| Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Oh, Sung Yong | Oh, SY | 9 |
페이지 이동: